Eyeworld

MARCH 2021 | EYEWORLD | 97 G Options to reduce postop cataract surgery drops for glaucoma patients S tudies have shown that the addition of a second glaucoma medication re- duces adherence. 1 With that in mind, it makes sense that adding postop cataract surgery drops to a patient's existing glaucoma drop regimen could have the same effect. Newer steroid and NSAID options (and some off-label administration of antibi- otics) that are delivered either via injection or intracanalicular insert can help avoid compli- cating a patient's drop regimen that is already subject to non-compliance, instillation issues, potential for ocular surface agitation, and more. When EyeWorld spoke with Leon Herndon, MD, he said he had a patient who came in re- cently for her cataract postop visit with a moxi- floxacin bottle capped with a green Lumigan (bimatoprost, Allergan) top. "This happens," he said. Nathan Radcliffe, MD, said "things fall apart" when you add a steroid, antibiotic, and NSAID onto a complicated glaucoma drop regimen. "We see a lot of errors where instead of taking prednisolone four times a day, patients will take their glaucoma drop that's usually once a day four times a day. This creates problems with healing, more inflammation on the eye," he said. In addition to the confusion adding new drops (even short-term ones) causes, Dr. Radcliffe pointed out that they can negate, for a time, the glaucoma-related procedures that are often performed with cataract surgery to get patients off drops. "It's nice to be able to deliver on the prom- ise to reduce drops by actually doing so, not just trading their glaucoma drops for anti-inflamma- tory drops," he said. Dr. Herndon said he has used Dextenza (dexamethasone ophthalmic insert, Ocular Therapeutix) for more than a year for combined cataract surgery/MIGS patients. He said he in- jects intracameral moxifloxacin and inserts the Dextenza intracanalicular implant, finding it has worked well with MIGS like iStent (Glaukos), Hydrus (Ivantis), and Kahook Dual Blade (New World Medical). Dr. Radcliffe also said he'll use intracameral moxifloxacin, off-label obtained by a compound- ing pharmacy, putting it in the anterior cham- ber. Dextenza, he said, is put into the lacrimal puncta; Dexycu (dexamethasone intraocular suspension, EyePoint Pharmaceuticals) is inject- ed into the iridociliary sulcus forming a sphere Dextenza Source: Leon Herndon, MD continued on page 98 by Liz Hillman Editorial Co-Director About the physicians Leon Herndon, MD Professor of Ophthalmology Duke University School of Medicine Durham, North Carolina Nathan Radcliffe, MD Associate Clinical Professor New York Eye and Ear Infirmary of Mount Sinai New York, New York

• Blank Page
• Blank Page (1)